DERMAT
MEDICAL SUPPLIES

Nevisense 3.0 Skibase

A breakthrough in non-invasive detection of melanoma

Nevisense is the world's first objective diagnostic tool for the non-visual detection of malignant melanoma. By collecting and analysing precise electrical measurements in the epidermis and dermis, it provides reliable information that is not available through any other method. A simple procedure allows you to objectively evaluate suspicious lesions before excision.

The diagnostic challenge

Most dermatologists have confidence in the current methods of visual examination. However, the literature shows that the accuracy of the clinical diagnosis of cutaneous melanoma with or without dermoscopy is far from 100%.
The consequences of this uncertainty are twofold. On the one hand, life-threatening melanoma may be missed. On the other hand, for safety reasons, benign lesions are unnecessarily eliminated.

Nevisense addresses this by supplementing the examination process with reliable, objective information that leads to more reliable and accurate diagnoses.

The Nevisense Solution

With Nevisense, SciBase has developed an innovative method for improving accuracy in the detection of malignant melanoma. By using Electrical Impedance Spectroscopy (EIS), applied as a harmless electrical signal to the skin, Nevisense is able to provide a reliable, objective analysis of suspicious lesions, complementing the physician's regular clinical evaluations.

The Nevisense method is both safe and painless. By providing valuable diagnostic information that is not available through other methods, it allows physicians to make more informed decisions in difficult or borderline cases. Nevisense, used as a diagnostic tool, allows to increase diagnostic accuracy, leading to both early detection of malignant melanoma and a reduction in unnecessary biopsies.

Intended use

The Nevisense EIS functionality is intended for use in cutaneous lesions with one or more clinical or historical features of melanoma. Nevisense is designed to be used to obtain additional information before deciding on the most appropriate course of action for the patient. Nevisense should not be used to confirm a clinical diagnosis of melanoma.

The Nevisense EIS functionality is intended only for use by medical professionals trained in the clinical diagnosis of skin cancer. The output of Nevisense is part of the overall clinical assessment. The output of Nevisense should be used in conjunction with clinical and historical signs of melanoma to obtain additional

information before deciding on the most appropriate course of action.

The functionality of Nevisense View is intended for documentation and not for diagnostic purposes.

The system is also intended for research purposes in the general measurement of skin electrical impedance. Research measurements can be carried out with non-invasive or micro-invasive (spike) electrodes.